Solís OCA, Solís SJM

Language: Spanish
References: 15
Page: 9-18
PDF size: 112.90 Kb.

ABSTRACT

Objective: To analyze the role essential or optional for central obesity (CO) in the metabolic syndrome (MS) by the National Cholesterol Education Program-Adult Treatment Panel (NCEP ATP III) criteria in patients evaluated in a cardiology office. Methods: Case-control study of patients evaluated in the Cardiology Unit of a community hospital in August 2006 to June 2007. Inclusion criteria: a) patients of both sexes. Exclusion: a) severe systemic disease or terminal, b) acute coronary syndrome, c) severe systolic dysfunction, d) after lipid lowering treatment. Procedures: We performed complete medical history, measurement of waist circumference, body mass index (BMI), glucose, lipids and stress test, cardiac catheterization according to clinical situation. They were divided into 4 groups: 1) No MS/No CO) 2) No MS/CO 3) MS/CO) and 4) MS/No CO. Dependent variable: ischemic heart disease. Statistics: Descriptive, t-test, contingency tables, Chi square and odds ratios (OR). Data analysis using SPSS software. It was considered a significant p £ 0.05. Results: Of 130 patients, 49.23% were males and 50,769% females, with age 58.6 ± 11.66 years. Metabolic syndrome (MS), 63.84%, smokers: 28.46%, diabetics: 29.23% and with hypertension: 59.23%. Group 3 compared to 2, had higher BMI, 31.866 ± 5.297 vs 29.095 ± 3.129, waists wider 106.95 ± 9.936 vs 99.952 ± 8.28 cm, higher levels of glucose, 139.485 ± 63.767 vs 92.095 ± 9.07 mg/dL and triglyceride (TG), 229.488 ± 118.819 ± 139.966 vs 65.734 mg/dL (p ‹ 0.01 for all), with lower levels of high density lipoprotein (HDL-C), 42.586 ± 12.31 vs 49,605 ± 11.988 mg/dL, p £ 0.05. Group 4 compared to 1 had higher levels of TG, 247.15 ±84.23 vs 155.25 ± 78.5 mg/dL and lower HDL-C, 34.14 ± 5.567 vs 44.132 ± 9.7 mg/dL (p ‹ 0.01 for both) and higher levels of glucose, 130.37 ± 47.28 vs 96.88 ± 34.43 mg/dL, p ‹ 0.05. In comparison, subjects with CO vs those without it, had the highest BMI, 31.2 ± 4.99 vs 25.42 ± 2.84, larger waists, 104.98 ± 9.93 vs 90.45 ± 8.64 cm (p ‹ 0.01 for both) and higher levels of glucose, 128.05 ± 59.23 vs 109.14 ± 42.31 mg/dL (p £ 0.05), without differences in levels of lipids and age. Were associated with CO the MS, OR 5.18 (95% CI 2.8116 to 9.5579) diabetes, OR 1.80 (95% CI of 0.956 to 3.3978), sedentary lifestyle, OR 2.22 (95% in 1.265 to 3.9202) and hypertension, OR 2.02 (95% in 1.464 to 3.5686), without demonstrated association with ischemic heart disease. Conclusion: The presence of CO in this group of patients was primarily indicative of higher val ues of glucose and body mass, significantly related to a sedentary lifestyle, metabolic syndrome, hypertension and diabetes, showing no direct relationship with ischemic heart disease. Our data suggest an optional role of central obesity as a criterion of metabolic syndrome.

REFERENCES

1. Lorenzo C, Williams K, González-Villalpando C, Haffner SM. The prevalence of the metabolic syndrome did not increase in Mexico city between 1990-1992 and 1997-1999 despite more central obesity. Diabetes Care 2005; 28: 2480-2485.

2. McLellan F. Obesity rising to alarming levels around the world. Lancet 2002; 359: 1412.

3. Agnieszka B, Ehud U. The obesity epidemic and its cardiovascular consequences. Curr Opin Cardiol 2006; 21; 353-360.

4. Koster A, Leitzmann MF, Schatzkin A, Mouw T, Adams K, Van Eijk JT et al. Waist circumference and mortality. Am J Epidemiol 2008; 167: 1465-1475.

5. McNeill AM, Schmide M, Rosamond W, East H, Girman C, Ballantyne C et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.

6. de Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Galloway JM et al, for the Strong Heart Study Investigators. Prognostic impact of the metabolic syndrome by different defintions in a population with high prevalence of obesity and diabetes. Diabetes Care 2007; 20: 1851-1856.

7. Malik Sh, Wong ND, Franklin SS, Kamath TV, L´Italien GJ, Pío JR et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.

8. Pineda CA. Síndrome metabólico: definición, historia, criterios. Colomb Med 2008; 39: 96-106.

9. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH et al. Risk factors for myocardial infarction in women and man: insights from in the INTERHEART study. Eur Heart J 2008; 29: 932-940.

10. Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KAA, Smith SC et al. International day for the evaluation of abdominal obesity (IDEA). A study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116: 1942-1951.

11. Lee J, Ma S, Heng D, Tan CE, Chew SK, Huges K et al. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 2007; 30: 343-347.

12. Benetos A, Thomas F, Pannier B, Bean K, Jégo B, Guize L. All-cause and cardiovascular mortality using the different definitions of metabolic syndrome. Am J Cardiol 2008; 102: 188-191.

13. Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome. Prospective analyses of mortality in men. Diabetes Care 2006; 29: 404-409.

14. Razak F, Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R et al, for the SHARE Investigators. Defining obesity cut points in a multiethnic population. Circulation 2007; 115: 2111-2118.

15. Ryan M, Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol 2008; 102: 40-46.